274 related articles for article (PubMed ID: 18490075)
21. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3.
Li WC; Ye SL; Sun RX; Liu YK; Tang ZY; Kim Y; Karras JG; Zhang H
Clin Cancer Res; 2006 Dec; 12(23):7140-8. PubMed ID: 17145839
[TBL] [Abstract][Full Text] [Related]
22. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
[TBL] [Abstract][Full Text] [Related]
23. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
[TBL] [Abstract][Full Text] [Related]
24. Total alkaloids of Rubus alceifolius Poir inhibit tumor angiogenesis through suppression of the Notch signaling pathway in a mouse model of hepatocellular carcinoma.
Zhao J; Lin W; Cao Z; Zhuang Q; Zheng L; Peng J; Hong Z
Mol Med Rep; 2015 Jan; 11(1):357-61. PubMed ID: 25333354
[TBL] [Abstract][Full Text] [Related]
25. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts.
Kolb EA; Kamara D; Zhang W; Lin J; Hingorani P; Baker L; Houghton P; Gorlick R
Pediatr Blood Cancer; 2010 Jul; 55(1):67-75. PubMed ID: 20486173
[TBL] [Abstract][Full Text] [Related]
26. Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts.
Zhou F; Hu J; Shao JH; Zou SB; Shen SL; Luo ZQ
J Cancer Res Clin Oncol; 2012 Nov; 138(11):1879-90. PubMed ID: 22736027
[TBL] [Abstract][Full Text] [Related]
27. Suppression of vascular endothelial growth factor via inactivation of eukaryotic elongation factor 2 by alkaloids in Coptidis rhizome in hepatocellular carcinoma.
Tan HY; Wang N; Tsao SW; Zhang Z; Feng Y
Integr Cancer Ther; 2014 Sep; 13(5):425-34. PubMed ID: 24363282
[TBL] [Abstract][Full Text] [Related]
28. Molecular targeting of VEGF/VEGFR signaling by the anti-VEGF monoclonal antibody BD0801 inhibits the growth and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo.
Liu L; Qin S; Zheng Y; Han L; Zhang M; Luo N; Liu Z; Gu N; Gu X; Yin X
Cancer Biol Ther; 2017 Mar; 18(3):166-176. PubMed ID: 28368741
[TBL] [Abstract][Full Text] [Related]
29. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.
Dickson PV; Hamner JB; Sims TL; Fraga CH; Ng CY; Rajasekeran S; Hagedorn NL; McCarville MB; Stewart CF; Davidoff AM
Clin Cancer Res; 2007 Jul; 13(13):3942-50. PubMed ID: 17606728
[TBL] [Abstract][Full Text] [Related]
30. The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts.
Bozec A; Etienne-Grimaldi MC; Fischel JL; Sudaka A; Toussan N; Formento P; Milano G
Oral Oncol; 2011 May; 47(5):340-4. PubMed ID: 21421338
[TBL] [Abstract][Full Text] [Related]
31. Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma.
Huynh H; Ngo VC; Choo SP; Poon D; Koong HN; Thng CH; Toh HC; Zheng L; Ong LC; Jin Y; Song IC; Chang AP; Ong HS; Chung AY; Chow PK; Soo KC
Curr Cancer Drug Targets; 2009 Sep; 9(6):738-47. PubMed ID: 19754358
[TBL] [Abstract][Full Text] [Related]
32. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma.
Semela D; Piguet AC; Kolev M; Schmitter K; Hlushchuk R; Djonov V; Stoupis C; Dufour JF
J Hepatol; 2007 May; 46(5):840-8. PubMed ID: 17321636
[TBL] [Abstract][Full Text] [Related]
33. Effect of vascular endothelial growth factor inhibition on endometrial implant development in a murine model of endometriosis.
Ricci AG; Olivares CN; Bilotas MA; Meresman GF; Barañao RI
Reprod Sci; 2011 Jul; 18(7):614-22. PubMed ID: 21266664
[TBL] [Abstract][Full Text] [Related]
34. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
35. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
Huynh H; Ngo VC; Fargnoli J; Ayers M; Soo KC; Koong HN; Thng CH; Ong HS; Chung A; Chow P; Pollock P; Byron S; Tran E
Clin Cancer Res; 2008 Oct; 14(19):6146-53. PubMed ID: 18829493
[TBL] [Abstract][Full Text] [Related]
36. (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis.
Shirakami Y; Shimizu M; Adachi S; Sakai H; Nakagawa T; Yasuda Y; Tsurumi H; Hara Y; Moriwaki H
Cancer Sci; 2009 Oct; 100(10):1957-62. PubMed ID: 19558547
[TBL] [Abstract][Full Text] [Related]
37. Xenografts of human hepatocellular carcinoma: a useful model for testing drugs.
Huynh H; Soo KC; Chow PK; Panasci L; Tran E
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4306-14. PubMed ID: 16857806
[TBL] [Abstract][Full Text] [Related]
38. [Effects of Rapamycin on angiogenesis and tumor progression in human hepatocellular carcinoma implantation mice].
Zhang J; Li H; Wang GS; Jiang N; Yang Y; Chen GH
Zhonghua Wai Ke Za Zhi; 2009 Sep; 47(18):1403-5. PubMed ID: 20092777
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma.
Piguet AC; Semela D; Keogh A; Wilkens L; Stroka D; Stoupis C; St-Pierre MV; Dufour JF
J Hepatol; 2008 Jul; 49(1):78-87. PubMed ID: 18486258
[TBL] [Abstract][Full Text] [Related]
40. ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft.
Jasinghe VJ; Xie Z; Zhou J; Khng J; Poon LF; Senthilnathan P; Glaser KB; Albert DH; Davidsen SK; Chen CS
J Hepatol; 2008 Dec; 49(6):985-97. PubMed ID: 18930332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
